Functional characterization of Foxp3-specific spontaneous immune responses

[1]  M. Boucher,et al.  Abstract 1674: Inhibition of GSK3 reduces p70S6K activity and promotes autophagy independently of the JNK-cJun pathway. , 2013 .

[2]  M. Donia,et al.  HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. , 2013, Cancer research.

[3]  Hiroaki Tanaka,et al.  Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival , 2012, Nature Medicine.

[4]  E. Jaffee,et al.  Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. , 2012, Cancer research.

[5]  S. Steinberg,et al.  Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. , 2012, Blood.

[6]  J. Becker,et al.  Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma , 2012, Cancer Immunology, Immunotherapy.

[7]  K. Tarte,et al.  Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells , 2012, Leukemia.

[8]  C. Geisler,et al.  Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome , 2012, Leukemia.

[9]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[10]  T. Holderried,et al.  Immunomodulatory effects of anti-angiogenic drugs , 2011, Leukemia.

[11]  I. Svane,et al.  Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2. , 2011, Cancer research.

[12]  I. Svane,et al.  Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. , 2011, Blood.

[13]  G. Prendergast,et al.  Zinc Protoporphyrin IX Stimulates Tumor Immunity by Disrupting the Immunosuppressive Enzyme Indoleamine 2,3-Dioxygenase , 2010, Molecular Cancer Therapeutics.

[14]  E. Gilboa,et al.  Vaccination against Foxp3(+) regulatory T cells aggravates atherosclerosis. , 2010, Atherosclerosis.

[15]  C. Klemke,et al.  FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome. , 2009, The Journal of investigative dermatology.

[16]  L. Bullinger,et al.  Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia , 2009, Leukemia.

[17]  T. Nomura,et al.  CTLA-4 Control over Foxp3+ Regulatory T Cell Function , 2008, Science.

[18]  C. Geisler,et al.  Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome , 2008, Leukemia.

[19]  Michael T. McManus,et al.  Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity , 2008, The Journal of experimental medicine.

[20]  A. Rudensky,et al.  Differentiation of regulatory Foxp3+ T cells in the thymic cortex , 2008, Proceedings of the National Academy of Sciences.

[21]  J. Bluestone,et al.  Human regulatory T cells: role in autoimmune disease and therapeutic opportunities , 2008, Immunological reviews.

[22]  J. Roliński,et al.  Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response , 2008, Leukemia.

[23]  C. Thoburn,et al.  Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma , 2008, Leukemia & lymphoma.

[24]  M. Peter,et al.  How apoptosis got the immune system in shape , 2007, European journal of immunology.

[25]  K. Rossen,et al.  FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival , 2007, Leukemia.

[26]  Helen Y Wang,et al.  Regulatory T cells and cancer. , 2007, Current opinion in immunology.

[27]  F. Holstege,et al.  FOXO3a Induces Differentiation of Bcr-Abl-transformed Cells through Transcriptional Down-regulation of Id1* , 2007, Journal of Biological Chemistry.

[28]  T. Schumacher,et al.  Design and use of conditional MHC class I ligands , 2006, Nature Medicine.

[29]  E. Gilboa,et al.  Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. , 2005, The Journal of clinical investigation.

[30]  M. Piris,et al.  FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma , 2005, Leukemia.

[31]  S. Hadrup,et al.  Evidence for involvement of clonally expanded CD8+ T cells in anticancer immune responses in CLL patients following nonmyeloablative conditioning and hematopoietic cell transplantation , 2005, Leukemia.

[32]  H. Stauss,et al.  Antigen-specific cellular immunotherapy of leukemia , 2005, Leukemia.

[33]  V. Godfrey,et al.  The Scurfy mutation of FoxP3 in the thymus stroma leads to defective thymopoiesis , 2005, The Journal of experimental medicine.

[34]  J. Becker,et al.  Identification of an HLA-A1 restricted CTL epitope from Mcl-1 , 2005, Leukemia.

[35]  S. Sakaguchi,et al.  Phenotypic and functional relationship between adult T-cell leukemia cells and regulatory T cells , 2005, Leukemia.

[36]  M. Baseler,et al.  The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity , 2003, Journal of Translational Medicine.

[37]  R. Koup,et al.  Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. , 2003, Journal of immunological methods.

[38]  R. Dummer,et al.  Proliferation of CD30+ T-helper 2 lymphoma cells can be inhibited by CD30 receptor cross-linking with recombinant CD30 ligand. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2003 .

[40]  L. Fugger,et al.  Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules , 2000, Leukemia.

[41]  T. Elliott,et al.  Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. , 1999, Journal of immunology.

[42]  L. Hsiao,et al.  A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. , 1997, Journal of immunological methods.

[43]  W. Heath,et al.  Induction of a CD8+ Cytotoxic T Lymphocyte Response by Cross-priming Requires Cognate CD4+ T Cell Help , 1997, The Journal of experimental medicine.

[44]  J. Hobson,et al.  Sleep: Sleep the Beloved Teacher? , 1995, Current Biology.

[45]  H. Rammensee,et al.  MHC molecules as peptide receptors. , 1993, Current opinion in immunology.

[46]  A. Liston,et al.  Regulatory T Cells , 2011, Methods in Molecular Biology.

[47]  J. Roliński,et al.  The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide , 2008, Leukemia.

[48]  G. Coukos,et al.  Regulatory T cells: a new frontier in cancer immunotherapy. , 2008, Advances in experimental medicine and biology.

[49]  E. Gilboa,et al.  Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. , 2007, Cancer research.